Dowgate research note30 Aug 2023 09:57
'Belluscura has signed an exclusive 10yr Licence and Royalty Agreement with InnoMax that we view as transformational and we raise our target price to 125p (100p). Belluscura has announced that it has entered into an exclusive Licence, Marketing and Distribution Agreement with its global manufacturing partner InnoMax for China, Hong Kong, Macau and Singapore. The Agreement will cover the X-PLOR following its registration, which is due later this year, and DISCOV-R in 2024. Belluscura will receive royalties on units sold, with annually increasing minimum royalties over the 10yr term of the agreement, and a profit share on accessory sales. The exclusive licence is for a minimum of five years but can be revoked by Belluscura if sales targets are not met, in which case it would convert to a non-exclusive licence. The minimum royalties are $27.5m/£22m if the licence is converted to non-exclusive in year 6, up to $55m/£44m if the exclusive licence runs for the whole term. We highlight that these are minimum guaranteed royalties and given the size of the Chinese market, could be significantly exceeded" - if that doesn't make you bullish you're in the wrong game